Lycke J - Search Results

1

COVID-19 clinical outcomes and DMT of MS patients and population-based controls.

Longinetti E, Bower H, McKay KA, Englund S, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Mellergård J, Olsson T, Piehl F, Frisell T. Longinetti E, et al. Among authors: lycke j. Ann Clin Transl Neurol. 2022 Sep;9(9):1449-1458. doi: 10.1002/acn3.51646. Epub 2022 Aug 22. Ann Clin Transl Neurol. 2022. PMID: 35993445 Free PMC article.

2

No evidence for spumavirus or oncovirus infection in relapsing-remitting multiple sclerosis.

Svenningsson A, Lycke J, Svennerholm B, Gronowitz S, Andersen O. Svenningsson A, et al. Among authors: lycke j. Ann Neurol. 1992 Nov;32(5):711-4. doi: 10.1002/ana.410320518. Ann Neurol. 1992. PMID: 1333176

3

Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden.

Svenningsson A, Runmarker B, Lycke J, Andersen O. Svenningsson A, et al. Among authors: lycke j. Acta Neurol Scand. 1990 Sep;82(3):161-8. doi: 10.1111/j.1600-0404.1990.tb04483.x. Acta Neurol Scand. 1990. PMID: 2270743

4

Human spumaretrovirus antibody reactivity in multiple sclerosis.

Lycke J, Svennerholm B, Svenningsson A, Muranyi W, Flügel RM, Andersen O. Lycke J, et al. J Neurol. 1994 Feb;241(4):204-9. doi: 10.1007/BF00863769. J Neurol. 1994. PMID: 8195818

5

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.

Andersen O, Lycke J, Tollesson PO, Svenningsson A, Runmarker B, Linde AS, Aström M, Gjörstrup P, Ekholm S. Andersen O, et al. Among authors: lycke j. Neurology. 1996 Oct;47(4):895-900. doi: 10.1212/wnl.47.4.895. Neurology. 1996. PMID: 8857715 Clinical Trial.

6

Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.

Lycke J, Svennerholm B, Hjelmquist E, Frisén L, Badr G, Andersson M, Vahlne A, Andersen O. Lycke J, et al. J Neurol. 1996 Mar;243(3):214-24. doi: 10.1007/BF00868517. J Neurol. 1996. PMID: 8936350 Clinical Trial.

7

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.

Andersen O, Lycke J, Tollesson PO, Svenningsson A, Runmarker B, Linde AS, Aström M, Gjörstrup P, Ekholm S. Andersen O, et al. Among authors: lycke j. Mult Scler. 1996 Jul;1(6):348. doi: 10.1177/135245859600100613. Mult Scler. 1996. PMID: 9345415 Clinical Trial. No abstract available.

8

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS.

Malmeström C, Haghighi S, Rosengren L, Andersen O, Lycke J. Malmeström C, et al. Among authors: lycke j. Neurology. 2003 Dec 23;61(12):1720-5. doi: 10.1212/01.wnl.0000098880.19793.b6. Neurology. 2003. PMID: 14694036 Clinical Trial.

9

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T. Holmén C, et al. Among authors: lycke j. Mult Scler. 2011 Jun;17(6):708-19. doi: 10.1177/1352458510394701. Epub 2011 Jan 12. Mult Scler. 2011. PMID: 21228027

10

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

Gunnarsson M, Malmeström C, Axelsson M, Sundström P, Dahle C, Vrethem M, Olsson T, Piehl F, Norgren N, Rosengren L, Svenningsson A, Lycke J. Gunnarsson M, et al. Among authors: lycke j. Ann Neurol. 2011 Jan;69(1):83-9. doi: 10.1002/ana.22247. Epub 2010 Dec 8. Ann Neurol. 2011. PMID: 21280078

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

175 results

Search Page

Filters